Advertisement

Topics

Principia Company Profile

17:29 EST 14th November 2018 | BioPortfolio

Principia serves the global plastics industry through research products and strategy consulting services aimed at profitable growth, helping clients grow market share and revenues and improve margins. Principia is headquartered in suburban Philadelphia, with offices and affiliates worldwide. For more information about the report, please contact Ken Jacobson or visit http://www.principiareports.com/offer/offer-hpp2014.php. Visit www.PrincipiaConsulting.com to learn more about Principia’s strategy consulting services.


News Articles [8 Associated News Articles listed on BioPortfolio]

Principia Biopharma Reports Third Quarter Financial Results

SOUTH SAN FRANCISCO, Calif., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a clinical-stage biopharmaceutical company dedicated to bringing transformative oral therapie...

Principia Biopharma Announces Pricing of Initial Public Offering

SOUTH SAN FRANCISCO, Calif., Sept. 13, 2018 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Principia or the Company, Nasdaq: PRNB), a clinical-stage biopharmaceutical company dedicated to bringing t...

Principia Biopharma Appoints Dolca Thomas, M.D. as Chief Medical Officer

- Succession designed to lead Principia through next phase of growth as a clinical-stage company - SOUTH SAN FRANCISCO, Calif., Oct. 24, 2018 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasda...

Principia Achieves $10 Million in Additional Milestones Related to Development of PRN2246/SAR442168

-- Additional milestones achieved under the Sanofi collaboration which is focused on treating diseases of the central nervous system -- SOUTH SAN FRANCISCO, Calif., Oct. 16, 2018 (GLOBE NEWSWIR...

Principia Biopharma to Present at 27th Annual Credit Suisse Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a clinical-stage biopharmaceutical company dedicated to bringing transformative oral therapie...

Principia Biopharma Announces PRN1008 Receives Orphan-Drug Designation from FDA for Treatment of Immune Thrombocytopenic Purpura

SOUTH SAN FRANCISCO, Calif., Oct. 19, 2018 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a clinical-stage biopharmaceutical company dedicated to bringing transformative oral therapie...

Principia Biopharma to Present at 2018 Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology

SOUTH SAN FRANCISCO, Calif., Sept. 26, 2018 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a clinical-stage biopharmaceutical company dedicated to bringing transformative oral therapi...

Principia Biopharma Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

SOUTH SAN FRANCISCO, Calif., Sept. 18, 2018 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Principia or the Company) (Nasdaq: PRNB), a clinical-stage biopharmaceutical company dedicated to bringing ...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [0 Results]

None

More Information about "Principia" on BioPortfolio

We have published hundreds of Principia news stories on BioPortfolio along with dozens of Principia Clinical Trials and PubMed Articles about Principia for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Principia Companies in our database. You can also find out about relevant Principia Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record